Entry Point Capital, LLC Biocryst Pharmaceuticals Inc Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
258Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$159 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$150 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$100 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$74.6 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$70.4 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.48B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...